{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:58Z","timestamp":1772136418634,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"United States Department of Defense | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-12-D-0003 0019"],"award-info":[{"award-number":["HDTRA1-12-D-0003 0019"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of humane endpoints is critical for refining scientific studies involving animals. Body weight and clinical signs of disease data collected in four recent studies assessing medical countermeasures for utility against the disease melioidosis in mice were further analyzed. Here we used this information to ascertain whether a suitable alternative humane endpoint could be identified. A total of 66 possible alternative humane endpoints were explored, which varied the threshold values of the \u2018percentage body weight loss post-challenge\u2019 and \u2018the clinical signs over time\u2019 following cessation of treatment. The findings indicated a suitable alternative endpoint of a percentage weight loss threshold of 25%, and\/or using an average total clinical signs score \u22655 over a 48-h period. This endpoint resulted in a sizeable reduction in median \u2018sign-days\u2019 (total clinical score multiplied by the number of days remaining in study) per mouse of 21\u2009days (ranging from 8 to 56 between studies), while maintaining 100% sensitivity and 93% specificity (ranging from 79% to 97% between studies). In addition, the risk of altering the scientific outcome of each study remained low when utilizing this new endpoint. In conclusion, current humane endpoints in this setting can be refined without negatively impacting the key study findings.<\/jats:p>","DOI":"10.1038\/s41684-025-01667-5","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:02:30Z","timestamp":1767693750000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploration of refined humane endpoints for melioidosis in BALB\/c mice"],"prefix":"10.1038","volume":"55","author":[{"given":"Michael P.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay B.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah V.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-624X","authenticated-orcid":false,"given":"Thomas C.","family":"Maishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1667_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/QCO.0000000000000869","volume":"35","author":"BJ Currie","year":"2022","unstructured":"Currie, B. J. Melioidosis and Burkholderia pseudomallei: progress in epidemiology, diagnosis, treatment and vaccination. Curr. Opin. Infect. Dis. 35, 517\u2013523 (2022).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1667_CR2","doi-asserted-by":"publisher","unstructured":"Limmathurotsakul, D. et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. https:\/\/doi.org\/10.1038\/nmicrobiol.2015.8 (2016).","DOI":"10.1038\/nmicrobiol.2015.8"},{"key":"1667_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1056\/NEJMra1204699","volume":"367","author":"WJ Wiersinga","year":"2012","unstructured":"Wiersinga, W. J., Currie, B. J. & Peacock, S. J. Melioidosis. N. Engl. J. Med. 367, 1035\u20131044 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1667_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijantimicag.2014.01.005","volume":"43","author":"D Dance","year":"2014","unstructured":"Dance, D. Treatment and prophylaxis of melioidosis. Int. J. Antimicrob. Agents 43, 310\u2013318 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"1667_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1128\/CMR.18.2.383-416.2005","volume":"18","author":"AC Cheng","year":"2005","unstructured":"Cheng, A. C. & Currie, B. J. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18, 383\u2013416 (2005).","journal-title":"Clin. Microbiol. Rev."},{"key":"1667_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s40475-017-0131-5","volume":"4","author":"K Amemiya","year":"2017","unstructured":"Amemiya, K. et al. Animal models for melioidosis. Curr. Trop. Med. Rep. 4, 208\u2013222 (2017).","journal-title":"Curr. Trop. Med. Rep."},{"key":"1667_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1006\/mpat.1997.0179","volume":"24","author":"AK Leakey","year":"1998","unstructured":"Leakey, A. K., Ulett, G. C. & Hirst, R. G. BALB\/c and C57Bl\/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathog. 24, 269\u2013275 (1998).","journal-title":"Microb. Pathog."},{"key":"1667_CR8","doi-asserted-by":"publisher","unstructured":"Nelson, M. et al. The BALB\/c mouse model for the evaluation of therapies to treat infections with aerosolized Burkholderia pseudomallei. Antibiotics https:\/\/doi.org\/10.3390\/antibiotics12030506 (2023).","DOI":"10.3390\/antibiotics12030506"},{"key":"1667_CR9","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/S0035-9203(08)70026-9","volume":"102","author":"RW Titball","year":"2008","unstructured":"Titball, R. W. et al. Burkholderia pseudomallei: animal models of infection. Trans. R Soc. Trop. Med. Hyg. 102, S111\u2013S116 (2008).","journal-title":"Trans. R Soc. Trop. Med. Hyg."},{"key":"1667_CR10","doi-asserted-by":"publisher","unstructured":"Barnes, K. B. et al. Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to Burkholderia pseudomallei. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00082-17 (2017).","DOI":"10.1128\/aac.00082-17"},{"key":"1667_CR11","doi-asserted-by":"publisher","unstructured":"Laws, T. R. et al. An investigation into the re-emergence of disease following cessation of antibiotic treatment in BALB\/c mice infected with inhalational Burkholderia pseudomallei. Antibiotics https:\/\/doi.org\/10.3390\/antibiotics11101442 (2022).","DOI":"10.3390\/antibiotics11101442"},{"key":"1667_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.934312","volume":"13","author":"KB Barnes","year":"2022","unstructured":"Barnes, K. B. et al. Investigation of a combination therapy approach for the treatment of melioidosis. Front. Microbiol. 13, 934312 (2022).","journal-title":"Front. Microbiol."},{"key":"1667_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00455-23","volume":"92","author":"KB Barnes","year":"2024","unstructured":"Barnes, K. B. et al. Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in BALB\/c mice. Infect Immun 92, e0045523 (2024).","journal-title":"Infect Immun"},{"key":"1667_CR14","unstructured":"Animals (Scientific Procedures) Act 1986 (ASPA, 1986); https:\/\/www.legislation.gov.uk\/ukpga\/1986\/14\/schedule\/1\/enacted"},{"key":"1667_CR15","unstructured":"The 3Rs (NC3Rs, 2024); https:\/\/nc3rs.org.uk\/who-we-are\/3rs"},{"key":"1667_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ijantimicag.2013.02.007","volume":"41","author":"KB Barnes","year":"2013","unstructured":"Barnes, K. B. et al. Trimethoprim\/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int. J. Antimicrob. Agents 41, 552\u2013557 (2013).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"1667_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jac\/dki039","volume":"55","author":"J Steward","year":"2005","unstructured":"Steward, J. et al. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection. J. Antimicrob. Chemother. 55, 523\u2013527 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"1667_CR18","first-page":"492","volume":"61","author":"RA Trammell","year":"2011","unstructured":"Trammell, R. A. & Toth, L. A. Markers for predicting death as an outcome for mice used in infectious disease research. Comp. Med. 61, 492\u2013498 (2011).","journal-title":"Comp. Med."},{"key":"1667_CR19","first-page":"555","volume":"36","author":"J Mei","year":"2019","unstructured":"Mei, J. et al. Refining humane endpoints in mouse models of disease by systematic review and machine learning-based endpoint definition. Altex 36, 555\u2013571 (2019).","journal-title":"Altex"},{"key":"1667_CR20","doi-asserted-by":"publisher","unstructured":"Morton, D. B. A model framework for the estimation of animal \u2018suffering\u2019: its use in predicting and retrospectively assessing the impact of experiments on animals. Animals https:\/\/doi.org\/10.3390\/ani13050800 (2023).","DOI":"10.3390\/ani13050800"},{"key":"1667_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2186331","volume":"14","author":"RS Dudis","year":"2023","unstructured":"Dudis, R. S. et al. Longitudinal temperature measurement can determine humane endpoints in BALB\/c mouse models of ESKAPEE infection. Virulence 14, 2186331 (2023).","journal-title":"Virulence"},{"key":"1667_CR22","first-page":"143","volume":"47","author":"JP Wong","year":"1997","unstructured":"Wong, J. P., Saravolac, E. G., Clement, J. G. & Nagata, L. P. Development of a murine hypothermia model for study of respiratory tract influenza virus infection. Lab Anim. Sci. 47, 143\u2013147 (1997).","journal-title":"Lab Anim. Sci."},{"key":"1667_CR23","doi-asserted-by":"publisher","first-page":"e45310","DOI":"10.1371\/journal.pone.0045310","volume":"7","author":"CR Molins","year":"2012","unstructured":"Molins, C. R. et al. Use of temperature for standardizing the progression of Francisella tularensis in mice. PLoS ONE 7, e45310 (2012).","journal-title":"PLoS ONE"},{"key":"1667_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1088\/0954-3899\/28\/10\/313","volume":"28","author":"AL Read","year":"2002","unstructured":"Read, A. L. Presentation of search results: the CLs technique. J. Phys. G 28, 2693 (2002).","journal-title":"J. Phys. G"},{"key":"1667_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4103\/ijmm.IJMM_17_140","volume":"35","author":"I Halim","year":"2017","unstructured":"Halim, I., Shaw, T., Tellapragada, C., Vandana, K. E. & Mukhopadhyay, C. Melioidosis: reinfection going incognito as relapse. Ind. J. Med. Microbiol. 35, 593\u2013596 (2017).","journal-title":"Ind. J. Med. Microbiol."},{"key":"1667_CR26","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1128\/JCM.43.12.6032-6034.2005","volume":"43","author":"B Maharjan","year":"2005","unstructured":"Maharjan, B. et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J. Clin. Microbiol. 43, 6032\u20136034 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"1667_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4269\/ajtmh.24-0007","volume":"111","author":"M Howes","year":"2024","unstructured":"Howes, M. & Currie, B. J. Melioidosis and activation from latency: the \u2018time bomb\u2019 has not occurred. Am. J. Trop. Med. Hyg. 111, 156\u2013160 (2024).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1667_CR28","doi-asserted-by":"publisher","unstructured":"Klimko, C. P. et al. Detection of low-level animal-to-animal transmission in BALB\/c mouse models of melioidosis. Front. Bacteriol. https:\/\/doi.org\/10.3389\/fbrio.2023.1303051 (2023).","DOI":"10.3389\/fbrio.2023.1303051"},{"key":"1667_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"1667_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br. J. Cancer 35, 1\u201339 (1977).","journal-title":"Br. J. Cancer"},{"key":"1667_CR31","unstructured":"Python 3 Reference Manual v. 3.10.13 (CreateSpace, 2009)."}],"container-title":["Lab Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01667-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:21:41Z","timestamp":1771251701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01667-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1667"],"URL":"https:\/\/doi.org\/10.1038\/s41684-025-01667-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5439132\/v1","asserted-by":"object"}]},"ISSN":["0093-7355","1548-4475"],"issn-type":[{"value":"0093-7355","type":"print"},{"value":"1548-4475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}